Methods. One hundred fifty-eight subjects participated in the Scleroderma Lung Study, with 79 each randomized to CYC and placebo arms. The study evaluated the results of 3 measures of health status: the Short Form 36 (SF-36), the Health Assessment Questionnaire (HAQ) disability index (DI), and Mahler's dyspnea index, and the results of 1 preference-based measure, the SF-6D. The differences in the HRQOL between the 2 groups at 12 months were calculated using a linear mixed model. Responsiveness was evaluated using the effect size. The proportion of subjects in each treatment group whose scores improved at least as much as or more than the minimum clinically important difference (MCID) in HRQOL measures was assessed.
scales of the SF-36, HAQ DI, and SF-6D at 12 months. In contrast, a higher proportion of patients who received CYC achieved the MCID compared with placebo in the HAQ DI score (30.9% versus 14.8%), transitional dyspnea index score (46.4% versus 12.7%), SF-36 MCS score (33.3% versus 18.5%), and SF-6D score (21.3% versus 3.8%).
Conclusion. One year of treatment with CYC leads to an improvement in HRQOL in patients with scleroderma lung disease.
The Scleroderma Lung Study (SLS) (1) is a double-blind, randomized, placebo-controlled trial of the effects of oral cyclophosphamide (CYC), administered for 1 year, on the course of forced vital capacity (FVC) (% predicted) in patients with evidence of active systemic sclerosis (SSc; scleroderma)-related interstitial lung disease (ILD), or scleroderma lung disease (SLD). The study showed that CYC produced a statistically significant, albeit modest, improvement in the 12-month FVC % predicted relative to placebo. In addition, results of the SLS showed a beneficial effect of CYC on the health-related quality of life (HRQOL). We have previously described in detail the baseline correlates of HRQOL from the SLS (2); the present report describes the impact of treatment on the change in the HRQOL of participants in the SLS from baseline to 12 months following initiation of the study drug by treatment assignment.
Study of HRQOL has originated from 2 fundamentally different approaches: health status assessment and health value/preference/utility assessment (3, 4) . Generally, health status measures describe a person's functioning in 1 or more domains (e.g., physical functioning and mental well-being). The SLS evaluated results obtained using 3 measures of health status: the Short Form 36 (SF-36), a generic measure; the Health Assessment Questionnaire (HAQ) disability index (DI), a musculoskeletal-targeted measure; and Mahler's dyspnea index, a dyspnea measure.
In contrast, health value/preference/utility measures assess the value or desirability of a state of health against an external metric (5) and summarize HRQOL using a single number. Preference-based measures can be determined either directly via a face-to-face interview with a subject or indirectly based on an individual's responses to a health status questionnaire. There are 2 major families of utilities: direct and indirect (or multiattribute) (4) . The direct preference-based scores can be assessed using the standard gamble (the risk of death, usually, that one would be willing to take to improve a state of health), the time tradeoff, and the rating scale (6) . Indirect preference-based scores use direct utility scores from a representative general population sample for a particular health state, and these scores are then applied to different health states captured by health status measurement instruments to derive a single score (7) . The SF-6D, an example of an indirect measure (8), derives preference-based scores from the SF-36.
A recent advancement in the study of HRQOL is the estimation of minimum clinically important difference (MCID), the smallest improvement in the score of a HRQOL measurement instrument that patients perceive as beneficial and that may lead to a change in disease management (9) . MCID can provide a benchmark for future design of SSc clinical trials by helping researchers and clinicians understand whether differences in HRQOL scores between 2 treatment groups are significant, or if changes within 1 group over time are clinically meaningful (4, 10) .
PATIENTS AND METHODS
Patient selection. Patients with SSc, as defined by the American College of Rheumatology (formerly, the American Rheumatism Association) classification criteria (11) , and a disease duration of Յ7 years (with onset defined as the date of the first typical non-Raynaud's phenomenon manifestation) were included in the current study. Other inclusion criteria were as follows: FVC Յ85% of predicted, dyspnea on exertion (grade 2 or higher on the magnitude of task component of Mahler's baseline dyspnea index [BDI]), and evidence of alveolitis on bronchoalveolar lavage (neutrophils Ն3%, eosinophils Ն2%) and/or ground-glass opacification on highresolution computed tomography (2) . The complete inclusion and exclusion criteria were recently published (1) .
Health status measurement instruments. Health status was assessed using SF-36 version 2, the HAQ DI, and Mahler's dyspnea index. The SF-36 is a generic measure of HRQOL consisting of 8 scales assessing 36 items (12, 13) . In addition, it includes a single item that assesses health transition. The 8 SF-36 scales can be summarized into physical component summary (PCS) and mental component summary (MCS) scores. The 8 scales and summary scores are standardized to responses from the US general population, for which the mean score is 50 and the standard deviation is 10 (14) . We used the SF-36 with a standard (4-week) recall period. The MCID for the SF-36 summary scores is between 2.5 and 5.0 in different arthritides (15) (16) (17) (Table 1) .
The HAQ DI is a disease-specific, musculoskeletaltargeted measure designed to assess functional ability in arthritis (18) . It is a self-administered 20-question instrument designed to assess a patient's level of upper and lower extremity functioning. The HAQ DI score is determined by summing the highest score in each of the 8 domains and dividing the sum by 8, yielding a score ranging from 0 (no disability) to 3 (severe disability). In the original HAQ DI, an additional grade of difficulty was added for patients using assistive/adaptive devices (such as canes or walkers). For consistency with other recent studies of SSc (19, 20) , the patients' responses were not modified for use of assistive/adaptive devices. An improvement of Ն0.14 and Ն0.22 in the HAQ DI score is considered to be the MCID in patients with SSc (10) and rheumatoid arthritis (21) , respectively.
Mahler's dyspnea index allows patients to assess their own level of dyspnea (22) . Dyspnea at baseline is assessed using the BDI. Scores on the BDI depend on ratings of 3 different categories: functional impairment, magnitude of task, and magnitude of effort. Limitation of ability in each of these 3 categories is graded from 0 (severe) to 4 (unimpaired). The ratings of the 3 categories are added to produce the total baseline score, ranging from 0 (severe) to 12 (no dyspnea). The transitional dyspnea index (TDI) assesses the change in dyspnea in each of the 3 categories, with scores ranging from Ϫ3 (major deterioration) to ϩ3 (major improvement) for each domain, with the TDI focal score being the sum of scores in the 3 domains (Ϫ9 to ϩ9). An improvement of 1 unit in the TDI is considered to be the MCID (23) .
Dyspnea was also assessed using the breathing visual analog scale (VAS; 0-100 mm), in which patients assessed, on a continuous scale, their own degree of difficulty in performing daily activities due to shortness of breath.
Preference-based measure. In the SF-6D (24), preference-based scores are derived from the SF-36. The SF-36 was revised into a health state classification system consisting of 6 dimensions (physical function, role limitation, social function, pain, mental health, and vitality), with a single HRQOL score derived from 11 items of the SF-36, covering the 6 dimensions. To assess preferences for the multi-attribute health states defined by the SF-6D, Brazier et al (24) used an interviewer-administered standard gamble in a representative sample from the UK. The weights for the US population have not been developed. The SF-6D scores ranged from 0.29 to 1.00, with a score of 1.00 indicating perfect or full health (24) . An improvement of 0.041 in the SF-6D score was considered to be the MCID (25) .
Statistical analysis. We analyzed the HRQOL data using the approach proposed by Osoba and colleagues (26) . Baseline descriptive statistics for the SF-36, HAQ DI, BDI, and SF-6D scores, and the percentage with floor and ceiling effects, were calculated. Floor and ceiling effects are the percentages of respondents scoring at the lowest and highest possible scale levels. These effects can influence responsiveness because they may limit a change in score over time (27) .
The baseline scores between the 2 groups were compared using Student's t-test. The instruments were administered every 3 months; we assessed the proportion of subjects in the CYC and placebo groups who completed the instruments at months 0, 3, 6, 9, and 12. Internal consistency reliability for multi-item scales was estimated using Cronbach's alpha (28) , with ␣ Ն 0.70 considered satisfactory for group comparisons (28) . We calculated the differences in the HRQOL measures between the 2 groups at 12 months using a linear mixed model and adjusting for the baseline value (29, 30) . Unadjusted strengths of association between HRQOL measures and physiologic impairment (FVC % predicted and diffusing capacity for carbon monoxide [DLCO] % predicted) at baseline were assessed using Pearson's correlation coefficients and interpreted as proposed by Franzblau (31) Because the number of patients in a study can affect statistical significance, we examined clinical significance in 2 additional ways, by calculating effect size and the proportion of patients whose change was greater than the MCID (32). Responsiveness to change was evaluated using the effect size (27) . Effect size was assessed using the following formula:
where M CYC Ϫ M PLAC is the average difference at month 12 between the CYC and placebo arms. Cohen's guide for interpreting effect size for HRQOL data is that a value of 0.20-0.49 represents a small change, 0.50-0.79 a medium change, and Ն0.80 a large change (20, 33) .
We assessed the proportion of patients whose SF-36 summary score improved by 5 units from baseline to month 12, the proportion of patients whose HAQ DI score improved by Ն0.14 and Ն0.22, the percentage of patients whose TDI changed by Ն1 unit, and the proportion of patients whose SF-6D score improved by Ն0.041. The aforementioned cut points were selected a priori (Table 1) . Based on the proportion of patients whose scores improved at least as much as or more than the MCID, we calculated the number needed to treat (NNT) (34) in order to achieve, on average, 1 patient with improved HRQOL:
As suggested by Osoba and colleagues (35), we did not use the Bonferroni adjustment because it assumes that the variables being tested are completely independent of each other; however, some SF-36, HAQ DI, and Mahler's dyspnea index scales are moderately correlated (13, 36, 37) . Statistical analyses were performed using SAS software, version 8.02 (SAS Institute, Cary, NC). P values less than 0.05 were considered significant.
RESULTS
The main findings of the SLS have recently been published (1) . Briefly, the mean Ϯ SD age of the study population was 48.5 Ϯ 12.3 years, most of the participants were women (71.0%), and the patients had a mean Ϯ SD disease duration of 3.1 Ϯ 2.1 years, mild functional disability as assessed by the HAQ DI (0.82 Ϯ Table 2 ). On average, the participants rated their physical and mental health as 1.7 SD and 0.1 SD, respectively, below that of the adjusted general US population (4). The SF-6D score was 0.63; in other words, on average, the participants in the SLS rated their health as 63% of perfect health.
Comparison of HRQOL scores in the CYC and placebo groups at baseline. At baseline, the mean HAQ DI score was significantly higher in the CYC group (0.95 Ϯ 0.66) compared with the placebo group (0.71 Ϯ 0.70) (P ϭ 0.03), whereas the SF-36 role physical (38.1 Ϯ 13.0) and mental health (50.2 Ϯ 10.1) scores were numerically higher in the placebo group compared with the CYC group (34.3 Ϯ 11.5 and 47.3 Ϯ 10.2; P ϭ 0.05 and P ϭ 0.07), respectively. Otherwise, there were no statistically significant differences in the HRQOL measures between the 2 groups ( Table 2) .
Reliability. Floor effects were more common in the HAQ DI (13.1%) than the BDI (1.24%); no floor effect was seen for the SF-36, SF-36 PCS, or SF-36 MCS scores. There were no ceiling effects for the 3 instruments. Internal consistency reliability scores were acceptable for all 3 measures: Cronbach's alpha was Ͼ0.90 for the total HAQ DI score, 0.81 for the total BDI score, and ranged from 0.89 for the social functioning scale to 0.90 for the mental health scale of the SF-36.
Change in the HRQOL over 12 months. The percentage of patients who completed the HRQOL measures (calculated as the percentage of patients with FVC % predicted data available at each followup visit) in the CYC and placebo groups, respectively, was 88.9% versus 90.1% at 3 months, 88.9% versus 88.9% at 6 months, 83.9% versus 80.3% at 9 months, and 85.2% versus 80.3% at 12 months. The difference was not statistically significant at any time point and therefore no statistical modeling was performed for missing data (38) .
Association between HRQOL and physiologic measure scores at 12 months. SF-36 PCS and breathing VAS showed a low degree of correlation with FVC % predicted and DLCO % predicted, SF-36 MCS showed no correlation with FVC % predicted or DLCO % pre- dicted, and TDI had a moderate degree of correlation with FVC % predicted and a low degree with DLCO % predicted ( Table 3) .
We assessed the change in the HRQOL using 3 different statistical approaches: statistical significance, responsiveness index, and the proportion of patients whose scores improved more than the MCID.
Statistical significance. After adjustment for baseline scores and application of a linear mixed model, the difference in the HAQ DI score, SF-36 role physical, general health, vitality, role emotional, and mental health scores, and the SF-36 MCS score between the CYC and placebo arms was statistically significant at 12 months (P Ͻ 0.05) ( Table 4 ). Since the TDI itself represents a change score and therefore was not administered at baseline, we assessed the impact of CYC on the TDI using the generalized estimating equation (39) . CYC had a statistically significant favorable impact on the TDI (P Ͻ 0.0001) ( Table 4) .
Responsiveness index. In comparison, the effect sizes were negligible (Ͻ0.20) for all of the scales and summary scores of the SF-36 and the HAQ DI at 12 months. The effect size was not calculated for the TDI. (Table 5) . Also, a greater proportion of patients who took CYC showed improvement in the health transition scale of the SF-36, a single-item measure determined by response to the question, "Compared to one year ago, how would you rate your health in general now?" In response, 47.0% of the patients who took CYC rated their health as somewhat better or much better, compared with 18.2% in the placebo group (P Ͻ 0.001). In comparison, only 24.2% in the CYC group rated their health somewhat worse or much worse, compared with 38.7% in the placebo group (P ϭ 0.01).
The proportion of patients whose scores improved more than the MCID was then used to assess the NNT (34, 40) in order to achieve, on average, 1 patient with improved HRQOL. For the HAQ DI, this was calculated as follows (Table 5): NNT ϭ 1/͑31% Ϫ 15%͒ ϫ 100 ϭ 6.25.
In other words, one would need to treat 6 or 7 patients with CYC to have 1 person experience a clinically meaningful improvement in his or her functional ability greater than that expected with placebo. Similarly, one would need to treat 3 patients with CYC to have 1 person experience a clinically meaningful difference in dyspnea compared with placebo (NNT ϭ 1/[46% Ϫ 13%] ϫ 100 ϭ 3).
Similar to health status measures, the SF-6D score showed a low degree of correlation with FVC % predicted and DLCO % predicted. At 12 months, the average SF-6D score was 0.65 in the CYC group and 0.63 in the placebo group and there was no statistically significant difference between the groups (P ϭ 0.54). The difference in effect size between the 2 treatment groups was negligible. In comparison, a higher proportion of patients who took CYC compared with placebo achieved MCID in the SF-6D score (21.3% versus 3.8%); one would need to treat 5 or 6 patients with CYC to have 1 person experience clinically meaningful improvement in his or her desirability of the current health state than expected with placebo.
DISCUSSION
The SLS is the first randomized, placebocontrolled trial to show a statistically significant, although modest, beneficial effect of CYC on the change in FVC % predicted compared with placebo after 12 months (1). The favorable effect of CYC on FVC was accompanied by parallel improvement in HRQOL measures, including functional disability, shortness of breath, and mental well-being, at the end of the 1-year study (1) .
At baseline, the participants had mild functional disability as assessed by the HAQ DI (mean Ϯ SD 0.82 Ϯ 0.69) and moderate dyspnea as assessed by Mahler's BDI (5.68 Ϯ 1.89) ( Table 2 ). In addition, the participants rated their physical and mental health 1.7 SD and 0.1 SD, respectively, below that of the general US population, which is consistent with the results of another study on SSc in which patients had moderate impairment in their SF-36 PCS score but a normal or near-normal SF-36 MCS score (20) . Although this was not formally assessed, the normal SF-36 MCS score may represent a psychological adjustment to the typically slow progression of SSc (41) .
HRQOL experts recommend the use of both disease-specific and generic HRQOL measures in clinical trials (4, 32) . The HAQ DI, a musculoskeletaltargeted measure, was able to demonstrate a statistically significant and clinically meaningful difference in functional ability between the CYC and placebo arms at 12 months. In contrast, changes in the SF-36 physical functioning scale and the SF-36 PCS were not significantly different between the 2 groups at 12 months. However, changes in the SF-36 vitality, role emotional, and mental health scales and the SF-36 MCS were significantly different between the 2 groups and favored CYC.
Since improvements in the SF-36 were most prominent in mental functioning scores, our findings suggest that improvement in the pulmonary and/or skin/musculoskeletal manifestations of ILD has a significant impact on mental well-being. This study confirms the opinion that disease-specific and generic HRQOL measures complement each other. Also, the associations between patient-reported outcomes and physiologic measures are only modest (42) (43) (44) . The correlation coefficients between HRQOL measures and physiologic measures ranged from none (0.03) to a moderate degree (0.41), confirming previous observations that HRQOL and physiologic measures complement each other (42) (43) (44) ). Analysis at the group level showed that treatment with CYC led to a statistically significant improvement in the HAQ DI, TDI, and SF-36 role physical, general health, vitality, role emotional, and mental health scales compared with placebo. Since statistical significance is dependent on the sample size, experts suggest also using a responsiveness index, such as effect size, to assess the clinical significance of such change (45) . In contrast to the statistically significant results, effect sizes of CYC on functional disability, dyspnea, and physical and mental functioning scales were negligible (all were Ͻ0.20). At a group level, a change of 0.20-0.49 in effect size is considered a clinically meaningful improvement (46, 47) .
We also assessed the proportion of patients between the 2 groups whose scores improved more than the MCID (4) at 1 year. In contrast to negligible effect size results that assess average scores, the scores of a higher proportion of patients who took CYC improved more than the MCID in HRQOL measures, including the HAQ DI score, TDI score, and SF-36 MCS score, compared with placebo.
We used the proportion of patients whose scores improved more than the MCID to assess the NNT (34, 40) in order to achieve, on average, 1 patient with improved HRQOL. This ranged from 3 patients for TDI to 40 patients for SF-36 PCS. In other words, one would need to treat 3 patients with CYC to have 1 person experience clinically meaningful improvement in dyspnea compared with placebo. We found these changes to be robust despite the group differences in baseline scores since ceiling effects did not occur.
Our results show a disparity between the modest physiologic benefit in SLS and the more obvious improvement in HRQOL measures in general, and breathlessness in particular. In other chronic respiratory diseases, small changes in lung function can have a significant clinical impact on symptoms and exercise tolerance (48) (49) (50) . It is therefore not surprising that the modest changes in lung function parameters are accompanied by a more obvious and clinically meaningful improvement in dyspnea.
There are several possible mechanisms that might explain the disparity between the rather marked improvement in dyspnea and the small improvement in FVC in our SLS ILD subjects, such as a reduction in inflammation in the lung, leading to decreased J receptor stimulation and decreased excessive drive to breathe, thus reducing dyspnea; reduction in skin thickness that could improve chest wall compliance and the exertion required for breathing; and musculoskeletal improvement that could lead to greater mobility, with a favorable "training" effect that improves exercise tolerance.
Health status measurement instruments can be used to inform and monitor outcomes in clinical encounters, monitor population health, estimate the burden of different conditions, and as end points in clinical trials (3, 4) . However, preference-based measures serve as "quality-adjustment factors" for calculating qualityadjusted life years (QALYs) in decision and costeffectiveness analyses that are used in resource allocation (3). A QALY takes into account both the quantity and quality of life generated by health care interventions (51) . For the SF-6D, a higher proportion of patients treated with CYC had a clinically meaningful change (21%) compared with those in the placebo group (4%; P ϭ 0.001). However, the difference in the average SF-6D scores at 1 year was not statistically significant (0.65 in the CYC group versus 0.63 in the placebo group; P ϭ 0.54). The reason for this discrepancy is likely related to the side effect profile of CYC. If significant numbers of individuals have adverse health consequences while at the same time clinical benefit is achieved in those able to take the medication, then this seemingly paradoxical outcome is understood. Since cost-effectiveness analyses incorporate average scores, from a societal perspective this may result in an unfavorable cost-effectiveness ratio for the use of CYC in the treatment of SSc-associated ILD.
Our study has some limitations. First, we cannot determine to what extent the beneficial effects of CYC on HRQOL are due to the modest improvement in lung function as measured by the FVC % predicted and/or improvement in extrapulmonary manifestations, such as skin thickness, muscle strength, and arthritis. The improvement in HRQOL may well be due to a combination of both since the SLS showed a statistically significant improvement in both FVC % predicted and skin score (1) . Whether this beneficial effect of CYC on the FVC and HRQOL measures will continue during the second year of the SLS treatment will be determined in future analyses.
Second, Mahler's dyspnea index was developed and validated in patients with chronic obstructive pulmonary disease (22, 23) . Although the dyspnea index has been previously used in patients with ILD (52), it has not been subjected to psychometric rigor in this latter group of patients. While this study could have provided the platform with which to validate Mahler's dyspnea index in ILD, unfortunately no respiratory-specific questionnaire (such as St. George's Respiratory Questionnaire) was administered.
Third, floor effects were more common in HAQ DI scores (13.1%) than in other measures. In other words, 13% of the participants did not report any functional disability. This is of significance since floor effects can limit the assessment of responsiveness to change (20, 27) . A lower proportion of floor effects (4.5% of the participants) in the HAQ DI score was seen in another SSc clinical trial (20) in which all participants had early diffuse SSc, compared with the inclusion of subjects with both limited and diffuse SSc in the current study.
In conclusion, CYC led to an improvement in the HRQOL of patients with SLD. Patient-reported outcomes and physiologic measures complemented each other, and we present different statistical methods that can be used to assess HRQOL in a randomized clinical trial.
